519 related articles for article (PubMed ID: 27077938)
41. Epigenetic regulation of Atrophin1 by lysine-specific demethylase 1 is required for cortical progenitor maintenance.
Zhang F; Xu D; Yuan L; Sun Y; Xu Z
Nat Commun; 2014 Dec; 5():5815. PubMed ID: 25519973
[TBL] [Abstract][Full Text] [Related]
42. LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML.
Cusan M; Cai SF; Mohammad HP; Krivtsov A; Chramiec A; Loizou E; Witkin MD; Smitheman KN; Tenen DG; Ye M; Will B; Steidl U; Kruger RG; Levine RL; Rienhoff HY; Koche RP; Armstrong SA
Blood; 2018 Apr; 131(15):1730-1742. PubMed ID: 29453291
[TBL] [Abstract][Full Text] [Related]
43. Targeting DNA hypermethylation: Computational modeling of DNA demethylation treatment of acute myeloid leukemia.
Przybilla J; Hopp L; Lübbert M; Loeffler M; Galle J
Epigenetics; 2017; 12(10):886-896. PubMed ID: 28758855
[TBL] [Abstract][Full Text] [Related]
44. Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
Ji YY; Lin SD; Wang YJ; Su MB; Zhang W; Gunosewoyo H; Yang F; Li J; Tang J; Zhou YB; Yu LF
Eur J Med Chem; 2017 Dec; 141():101-112. PubMed ID: 29031059
[TBL] [Abstract][Full Text] [Related]
45. A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancers.
Sugino N; Kawahara M; Tatsumi G; Kanai A; Matsui H; Yamamoto R; Nagai Y; Fujii S; Shimazu Y; Hishizawa M; Inaba T; Andoh A; Suzuki T; Takaori-Kondo A
Leukemia; 2017 Nov; 31(11):2303-2314. PubMed ID: 28210006
[TBL] [Abstract][Full Text] [Related]
46. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2.
Binda C; Valente S; Romanenghi M; Pilotto S; Cirilli R; Karytinos A; Ciossani G; Botrugno OA; Forneris F; Tardugno M; Edmondson DE; Minucci S; Mattevi A; Mai A
J Am Chem Soc; 2010 May; 132(19):6827-33. PubMed ID: 20415477
[TBL] [Abstract][Full Text] [Related]
47. Pure enantiomers of benzoylamino-tranylcypromine: LSD1 inhibition, gene modulation in human leukemia cells and effects on clonogenic potential of murine promyelocytic blasts.
Valente S; Rodriguez V; Mercurio C; Vianello P; Saponara B; Cirilli R; Ciossani G; Labella D; Marrocco B; Monaldi D; Ruoppolo G; Tilset M; Botrugno OA; Dessanti P; Minucci S; Mattevi A; Varasi M; Mai A
Eur J Med Chem; 2015 Apr; 94():163-74. PubMed ID: 25768700
[TBL] [Abstract][Full Text] [Related]
48. A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors.
Zheng YC; Ma J; Wang Z; Li J; Jiang B; Zhou W; Shi X; Wang X; Zhao W; Liu HM
Med Res Rev; 2015 Sep; 35(5):1032-71. PubMed ID: 25990136
[TBL] [Abstract][Full Text] [Related]
49. The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML.
Kahl M; Brioli A; Bens M; Perner F; Kresinsky A; Schnetzke U; Hinze A; Sbirkov Y; Stengel S; Simonetti G; Martinelli G; Petrie K; Zelent A; Böhmer FD; Groth M; Ernst T; Heidel FH; Scholl S; Hochhaus A; Schenk T
Leukemia; 2019 Nov; 33(11):2628-2639. PubMed ID: 31576004
[TBL] [Abstract][Full Text] [Related]
50. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
Morera L; Lübbert M; Jung M
Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
[TBL] [Abstract][Full Text] [Related]
51. Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.
Kim TK; Gore SD; Zeidan AM
Semin Hematol; 2015 Jul; 52(3):172-83. PubMed ID: 26111464
[TBL] [Abstract][Full Text] [Related]
52. LSD1: a viable therapeutic target in cutaneous squamous cell carcinoma?
Egolf S; Capell BC
Expert Opin Ther Targets; 2020 Jul; 24(7):671-678. PubMed ID: 32379508
[TBL] [Abstract][Full Text] [Related]
53. The epigenetic promotion of osteogenic differentiation of human adipose-derived stem cells by the genetic and chemical blockade of histone demethylase LSD1.
Ge W; Liu Y; Chen T; Zhang X; Lv L; Jin C; Jiang Y; Shi L; Zhou Y
Biomaterials; 2014 Jul; 35(23):6015-25. PubMed ID: 24794925
[TBL] [Abstract][Full Text] [Related]
54. Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia.
Braun TP; Coblentz C; Curtiss BM; Coleman DJ; Schonrock Z; Carratt SA; Callahan RL; Maniaci B; Druker BJ; Maxson JE
Proc Natl Acad Sci U S A; 2020 Jun; 117(24):13670-13679. PubMed ID: 32471953
[TBL] [Abstract][Full Text] [Related]
55. Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development.
Tsai CT; So CW
Oncogene; 2017 Mar; 36(13):1753-1759. PubMed ID: 27593928
[TBL] [Abstract][Full Text] [Related]
56. Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.
Duy C; Teater M; Garrett-Bakelman FE; Lee TC; Meydan C; Glass JL; Li M; Hellmuth JC; Mohammad HP; Smitheman KN; Shih AH; Abdel-Wahab O; Tallman MS; Guzman ML; Muench D; Grimes HL; Roboz GJ; Kruger RG; Creasy CL; Paietta EM; Levine RL; Carroll M; Melnick AM
Cancer Discov; 2019 Jul; 9(7):872-889. PubMed ID: 31076479
[TBL] [Abstract][Full Text] [Related]
57. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy.
Schulte JH; Lim S; Schramm A; Friedrichs N; Koster J; Versteeg R; Ora I; Pajtler K; Klein-Hitpass L; Kuhfittig-Kulle S; Metzger E; Schüle R; Eggert A; Buettner R; Kirfel J
Cancer Res; 2009 Mar; 69(5):2065-71. PubMed ID: 19223552
[TBL] [Abstract][Full Text] [Related]
58. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
[TBL] [Abstract][Full Text] [Related]
59. Tuning mTORC1 activity dictates the response of acute myeloid leukemia to LSD1 inhibition.
Abdel-Aziz AK; Pallavicini I; Ceccacci E; Meroni G; Saadeldin MK; Varasi M; Minucci S
Haematologica; 2020 Aug; 105(8):2105-2117. PubMed ID: 31537694
[TBL] [Abstract][Full Text] [Related]
60. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Stahl M; Gore SD; Vey N; Prebet T
Expert Opin Investig Drugs; 2016; 25(3):307-17. PubMed ID: 26807602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
